Patient and transplant characteristics
| Variables . | Missing data, n (%) . | All (N = 813) . | BMF/AA (n = 778) . | AML/MDS (n = 35) . | P value . |
|---|---|---|---|---|---|
| Year of transplant, n (%) | 0 | .03 | |||
| Before 2014 | 396 (49) | 372 (48) | 24 (79) | ||
| After 2014 | 417 (51) | 406 (52) | 11 (32) | ||
| Median age at transplant, y (IQR) | 0 | 8.8 (6.5-11.5) | 8.8 (6.5-11.4) | 9.9 (7.4-14.0) | .12 |
| Median interval between diagnosis and transplant, y (IQR) | 0 | 2.1 (0.8-4.5) | 2.1 (0.8-4.4) | 1.3 (0.4-5.9) | .27 |
| Male, n (%) | 4 (0.5) | 415 (51) | 396 (51) | 19 (54) | .85 |
| Donor, n (%) | 0 | .007 | |||
| MFD | 441 (54) | 431 (55) | 11 (31) | ||
| MUD | 162 (20) | 154 (20) | 20 (57) | ||
| MMFD/MMUD | 144 (18) | 133 (17) | 11 (31) | ||
| HID (≤ 8/10 HLA matching) | 66 (8) | 60 (8) | 6 (17) | ||
| Stem cell source, n (%) | 3 (0.4) | .503 | |||
| Marrow | 526 (65) | 506 (65) | 20 (57) | ||
| Peripheral blood | 226 (28) | 215 (30) | 11 (31) | ||
| CB | 51 (6) | 47 (6) | 4 (11) | ||
| Marrow + CB | 7 (1) | 7 (1) | 0 (0) | ||
| Ex vivo TCD, n (%) | 14 (2) | 87 (11) | 77 (10) | 10 (31) | <.001 |
| Conditioning regimen, n (%) | 6 (0.7) | ||||
| FluCy | 611 (75.7) | 591 (77) | 20 (57) | <.001 | |
| FluCy + other chemotherapy | 63 (7.8) | 53 (7) | 10 (29) | ||
| Non-FluCy conditioning | 133 (16.5) | 128 (17) | 5 (14) | ||
| Serotherapy, n (%) | 4 (0.5) | .03 | |||
| ATG | 620 (76) | 596 (77) | 24 (71) | ||
| Alemtuzumab | 86 (11) | 78 (10) | 8 (24) | ||
| None | 103 (13) | 101 (13) | 2 (6) | ||
| TBI | 29 (4) | <.001 | |||
| None | 688 (88) | 666 (89) | 22 (65) | ||
| 2-4 Gy | 90 (11) | 79 (11) | 11 (32) | ||
| >8 Gy | 6 (1) | 5 (1) | 1 (3) |
| Variables . | Missing data, n (%) . | All (N = 813) . | BMF/AA (n = 778) . | AML/MDS (n = 35) . | P value . |
|---|---|---|---|---|---|
| Year of transplant, n (%) | 0 | .03 | |||
| Before 2014 | 396 (49) | 372 (48) | 24 (79) | ||
| After 2014 | 417 (51) | 406 (52) | 11 (32) | ||
| Median age at transplant, y (IQR) | 0 | 8.8 (6.5-11.5) | 8.8 (6.5-11.4) | 9.9 (7.4-14.0) | .12 |
| Median interval between diagnosis and transplant, y (IQR) | 0 | 2.1 (0.8-4.5) | 2.1 (0.8-4.4) | 1.3 (0.4-5.9) | .27 |
| Male, n (%) | 4 (0.5) | 415 (51) | 396 (51) | 19 (54) | .85 |
| Donor, n (%) | 0 | .007 | |||
| MFD | 441 (54) | 431 (55) | 11 (31) | ||
| MUD | 162 (20) | 154 (20) | 20 (57) | ||
| MMFD/MMUD | 144 (18) | 133 (17) | 11 (31) | ||
| HID (≤ 8/10 HLA matching) | 66 (8) | 60 (8) | 6 (17) | ||
| Stem cell source, n (%) | 3 (0.4) | .503 | |||
| Marrow | 526 (65) | 506 (65) | 20 (57) | ||
| Peripheral blood | 226 (28) | 215 (30) | 11 (31) | ||
| CB | 51 (6) | 47 (6) | 4 (11) | ||
| Marrow + CB | 7 (1) | 7 (1) | 0 (0) | ||
| Ex vivo TCD, n (%) | 14 (2) | 87 (11) | 77 (10) | 10 (31) | <.001 |
| Conditioning regimen, n (%) | 6 (0.7) | ||||
| FluCy | 611 (75.7) | 591 (77) | 20 (57) | <.001 | |
| FluCy + other chemotherapy | 63 (7.8) | 53 (7) | 10 (29) | ||
| Non-FluCy conditioning | 133 (16.5) | 128 (17) | 5 (14) | ||
| Serotherapy, n (%) | 4 (0.5) | .03 | |||
| ATG | 620 (76) | 596 (77) | 24 (71) | ||
| Alemtuzumab | 86 (11) | 78 (10) | 8 (24) | ||
| None | 103 (13) | 101 (13) | 2 (6) | ||
| TBI | 29 (4) | <.001 | |||
| None | 688 (88) | 666 (89) | 22 (65) | ||
| 2-4 Gy | 90 (11) | 79 (11) | 11 (32) | ||
| >8 Gy | 6 (1) | 5 (1) | 1 (3) |